The company´s technology is applicable on proteins, peptides and small molecules and offers a unique half-life extension platform consisting of covalent as well as extended release PEGylation. The technology offers improved patient convenience, new patent lives and a substantial reduction in cost-of-goods.
QuiaPEG Pharmaceuticals
QuiaPEG Pharmaceuticals AB is an emerging biotech company developing biopharmaceuticals based on a proprietary, cutting-edge PEGylation technology platform.
